Drug
MD1003
MD1003 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(2)
Other(1)
Detailed Status
Terminated2
Completed2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
terminated240%
unknown120%
completed240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
NCT02967679
terminatedphase_1
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
NCT04252430
terminatedphase_1
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
NCT04252417
unknownphase_1
TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
NCT04168723
completedphase_2
Effect of MD1003 in Amyotrophic Lateral Sclerosis
NCT03114215
Clinical Trials (5)
Showing 5 of 5 trials
NCT02967679Phase 2
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
NCT04252430Phase 1
RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects
NCT04252417Phase 1
HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects
NCT04168723Phase 1
TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects
NCT03114215Phase 2
Effect of MD1003 in Amyotrophic Lateral Sclerosis
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5